The Effect of Vaginal Estrogen Cream on Subjective and Objective Symptoms of Urodynamic Stress Incontinence

Overview

This is a randomized, double blinded placebo controlled trial over a period of 3 months. Study subjects will be randomized into 2 groups: Those receiving drug (1gm of estrogen vaginal cream [EVC] at bed time 3 times a week), and those receiving placebo.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: May 2010

Detailed Description

1. This will be a randomized, double blinded placebo controlled trial over a period of 3 months. Study subjects will be randomized into 2 groups: Those receiving drug (1gm of estrogen vaginal cream [EVC] at bed time 3 times a week), and those receiving placebo. Study subjects will be patients diagnosed with stress urinary incontinence by urodynamic evaluation. They will have filled out the IIQ-7 and UDI-6 validated questionnaires as is routine for all patients being evaluated for stress incontinence. After enrollment and informed consent, their initial screening will include a Pap smear for vaginal maturation. 2. Subjects will then be seen at 4, 8 and 12 weeks. At each visit, they will turn in their medication tubes and receive new study medication. They will also be screened for any adverse reaction to the study medication at each visit. 3. At the end of the study period, the subjects will fill out the same validated questionnaire as they did at the beginning of the study and they will also have their urethral pressure profile and PAP smear repeated. 4. The urethral pressure profile is part of the standard complex urodynamic testing that all patients undergo for evaluation and diagnosis of urodynamic stress incontinence. Urethral Pressure Profile is a technique used to provide information about the ability of the urethra to prevent leakage. The Urethral Pressure Profile is a specific study, in which a special design catheter is pulled through the urethra at a slow, continuous rate. The resulting "bell shaped" curve illustrates the function of the urethra from the beginning of the bladder neck out through the meatus. 5. The placebo cream will be a pharmacologically inert formulation which will be packaged similarly to the active premarin cream and visually indistinguishable from the active drug to both the study subjects and researchers.

Interventions

  • Drug: Vaginal ERT
    • 1gm of estrogen vaginal cream [EVC] at bed time 3 times a week
  • Drug: Placebo
    • Placebo

Arms, Groups and Cohorts

  • Active Comparator: Vaginal ERT
    • Vaginal ERT cream 1 gm at bed time 3 times a week
  • Placebo Comparator: Placebo
    • 1gm of placebo at bed time 3 times a week

Clinical Trial Outcome Measures

Primary Measures

  • To determine the effects of vaginal estrogen replacement versus placebo on the subjective improvement of stress urinary incontinence symptoms with the use of validated questionnaires.
    • Time Frame: Exam at baseline and 12 weeks

Secondary Measures

  • Determine effects of vaginal ERT vs placebo on objective improvement in urethral function by comparing pre and post treatment urethral closure pressures. Determine incidence of UTIs at the beginning of study compared to the end of the study.
    • Time Frame: Exam at baseline and 12 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • English speaking – Postmenopausal women (No menses for a minimum period of 1 year) – Urodynamic stress urinary incontinence Exclusion Criteria:

  • History of breast or uterine cancer – History of venous thrombolic event – Hormone replacement therapy within 3 months of study – Sensitivity or allergy to premarin cream – Current use of any medications for urge or stress incontinence – Prior surgery for stress incontinence – Overactive bladder or Detrussor instability – Active vaginal/ bladder infection (patients will be treated and have a negative test for cure in order to be enrolled in the study) – History of pelvic or vaginal radiation therapy

Gender Eligibility: Female

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of California, Irvine
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Karen Noblett, MD, Principal Investigator, UCI Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.